General Information

Patient Reimbursement

Study Location: Frankfurt

Further Study Locations

Example Study Landing Page

Have you been diagnosed with asthma? The Medaimun Institute for Respiratory Diseases is looking for patients (both male and female, aged between 18 and 80) who suffer from asthma and are interested in participating in a clinical research study.

Study objective

The trial involves testing an oral inhalation medication combining budesonide and formoterol fumarate (BFF-MDI). This combination of medications is already approved for the treatment of asthma in the form of Symbicord® Turbuhaler®. The aim now is to investigate whether the medication can also be taken effectively using the budesonide metered-dose inhaler.

Start and duration of the study

The study will begin in spring 2026 and will run for 12 months, with 11 visits to the trial center and 3 telephone visits.

Amount of expense allowance

In addition to travel expenses, you will also be reimbursed for the time spent on visits. If you participate in the entire study, you will receive up to €2,190.

Medical care during the study

During the study, you will receive comprehensive medical care and examinations from specialist doctors. All study-related measures (medication, laboratory tests, medical examinations, etc.) will be paid for by the sponsor of the study.

How can I participate in the study?

If you are interested in participating in the study, we ask that you answer a few questions regarding the eligibility requirements. If you meet the requirements, a registration form will appear that you must complete.

 

The study has been approved by the competent federal authority and has received a positive assessment from the competent ethics committee. The study is registered under EU CT number: 2024-515717-17-00.

"*" oznacza pola wymagane

To pole jest używane do walidacji i powinno pozostać niezmienione.
Call Back Time

To pole jest ukryte podczas wyświetlania formularza